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Abstract
Objective This study compares the current regulatory
review process and good review practices at the Saudi
Food and Drug Authority (SFDA) with those of regulatory
agencies in Australia, Canada, and Singapore and identifies
opportunities for developing the SFDA as a Regional
Centre of Excellence.
Methods A questionnaire completed by the SFDA
included data regarding the organisation, key milestones,
review timelines, and good review practices of the agency.
Similar information was obtained within the same time-
frame (2014/2015) through the same standard question-
naire regarding the processes and practices for Health
Canada, Singapore’s Health Sciences Authority, and Aus-
tralia’s Therapeutic Goods Administration.
Results All four regulatory agencies have established
target times for scientific assessment and regulatory
review, examine dossier sections in parallel, and separate
company response time from overall timing. Additionally,
all four agencies have instituted good review practices
including standard operating procedures, templates, dossier
monitoring, and continuous improvement processes, and
assign a high priority to transparency in their relationships
with the public, healthcare professionals and industry. Of
the four agencies, however, only the SFDA requires a
Certificate of Pharmaceutical Product (CPP) at the time of
the submission and pricing negotiations before final pro-
duct approval.
Conclusions To assist the SFDA in its efforts to become a
Regional Centre of Excellence, it is suggested that the
agency explore a risk stratification approach to select
dossiers for verification, abridged, or full reviews; use
forms of certification other than the CPP; make pricing
negotiations independent to the review process; and intro-
duce a feedback process for the quality of the dossier.& Stuart Walker
swalker@cirsci.org
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Key Points
The Saudi Food and Drug Authority (SFDA), Health
Canada, Singapore’s Health Sciences Authority
(HSA), and Australia’s Therapeutic Goods
Administration (TGA) have all established target
times for scientific assessment and regulatory
review, examine dossier sections in parallel, and
separate company response time from overall timing.
The SFDA, Health Canada, the HSA, and the TGA
have all instituted good review practices; however,
only the SFDA requires a Certificate of
Pharmaceutical Product (CPP) for review and
completion of pricing negotiations before approval.
In its efforts to become a Regional Centre of
Excellence, the SFDA could explore a risk
stratification approach to select dossiers for
verification, abridged, or full reviews; use forms of
certification other than the CPP; make pricing
negotiations independent to the review process; and
introduce a feedback process for the quality of the
dossier.
1 Introduction
Pharmaceutical regulatory authorities are challenged in their
mandate to perform a transparent, timely review of pharma-
ceutical products for quality, safety, and efficacy. Their per-
formance against that challenge should be regularly assessed
against established international qualitative and quantitative
benchmarks and identified best practices and procedures to
allowagencies to evaluate their ownperformance, toprovide a
baseline against which the impact of change can be measured
and to develop realistic improvement initiatives to ultimately
ensure that patients in their jurisdictions have expeditious
access to innovative, safe, and effective medicines.
In 2015, Alsager et al. [1] conducted a review of the
performance of the Saudi Food and Drug Authority
(SFDA) to identify areas in which the agency excelled as
well as issues for improvement. The current assessment
compares SFDA performance, processes, and procedures
with those of three comparably sized, established interna-
tional regulatory agencies.
1.1 Saudi Arabia: A Growing Pharmaceutical
Market
The Kingdom of Saudi Arabia is one of the wealthiest in
the Middle East and African region and its economy
continues to grow. From 2014 to 2015, healthcare spending
increased 16 % in Saudi Arabia, rising from 103.2 billion
(bn) Saudi Arabian riyals (SAR) [27.5 bn US dollars
(USD)] to SAR 119.4 bn (USD 31.8 bn) [2]. Pharmaceu-
tical spending increased 12 % in that same time period,
climbing from SAR 28.4 bn (USD 7.6 bn) to SAR 31.8 bn
(USD 8.5 bn). Some of these increases can be traced to a
rapidly increasing population and the rising incidence and
burden of respiratory diseases, diabetes, hypertension, and
cancer [2].
In response to these conditions, the SFDA employs
stringent price control policies to constrain public and
private pharmaceutical costs and participates in the Gulf
Cooperation Council (GCC) drug pricing plan, but it is
expected that government support for private health
insurance enrolment will act to increase overall pharma-
ceutical expenditures [3].
1.2 The Saudi Food and Drug Authority
and the Gulf Cooperation Council
In 2009, the SFDA acquired responsibility for the regulation
of pharmaceuticals from the Saudi Arabia Ministry of
Health. Saudi Arabia is a member of the GCC, established
in 1981 to develop unified policies, regulations, and laws
among its member states, comprising Saudi Arabia, Kuwait,
Bahrain, Qatar, United Arab Emirates, Oman, and Yemen
[4]. The centralised procedure for pharmaceutical product
registration within the GCC has facilitated the development
of unified technical guidelines for the simultaneous regis-
tration of products in all member states; however, this
process has increased the time required for registration for
new products and used constrained regulatory resources in
all GCC jurisdictions, including Saudi Arabia.
1.3 Study Rationale
As the leading regulatory agency in the Gulf States, it is the
long-term goal of the SFDA to become an international
Centre of Regulatory Excellence and expedite patients’
access to medicines in the region. This study aimed to
compare current SFDA review timelines, processes, and
procedures with those of three international, mid-sized
regulatory agencies in order to identify areas of strength as
well as those requiring further improvement to facilitate
SFDA progress toward this goal.
2 Objectives
• Characterise the current regulatory review process used
at the SFDA, identifying agency review models as well
as key milestones and timelines.
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• Ascertain good review practice requirements, imple-
mentation, and measurement by the SFDA, including
those to ensure consistency, transparency, timeliness,
and predictability of the review process.
• Compare the review processes and practices of the
SFDA with those of the regulatory agencies in Canada,
Singapore, and Australia to identify areas in which the
SFDA excels as well as to suggest opportunities for
improvement in order to ultimately enhance patients’
access to new medicines.
3 Methods
The Centre for Innovation in Regulatory Science (CIRS)
has developed a three-part standardised questionnaire,
which was completed by SFDA personnel and used to
determine agency regulatory review process and practices.
This instrument was originally developed to gather infor-
mation about the regulatory systems in jurisdictions with
emerging pharmaceutical markets [5], and was subse-
quently used for a study of good review practices in the
Asia Pacific Economic Cooperation (APEC) region [6].
The first part of the questionnaire established the
organisation of the SFDA, including its structure, resour-
ces, and review models. Using regulatory process maps
developed by CIRS through its work with regulatory
agencies in mature and developing markets, the second part
of the questionnaire identified SFDA review milestones
and timelines for new active substances (NASs), where an
NAS is defined as a chemical, biological, or radiophar-
maceutical substance not previously authorised as a phar-
maceutical product in the country being studied.
The third part of the questionnaire examined SFDA
activities that contribute to the quality of the decision-
making process and those good review practices that have
been adopted at the agency to improve consistency,
transparency, timeliness, and predictability in the regula-
tory review. The results of the questionnaire were evalu-
ated by SFDA study participants for potential additions,
amendments, or comments.
Similar questionnaires were also completed and vali-
dated within the same timeframe (2014/2015) by Health
Canada, Singapore’s Health Sciences Authority (HSA),
and Australia’s Therapeutic Goods Administration (TGA).
In addition to enabling the compilation of important
information about the structure, processes, and practices of
international regulatory agencies, the use of the consistent
format and standardised terminology of the questionnaire
facilitates an accurate comparison among these organisa-
tions. Pharmaceutical company data for agency approval
timing was obtained directly from pharmaceutical
companies by CIRS as part of its ongoing study to
benchmark the approval times of global regulatory
agencies.
A complete analysis of the questionnaire results for
Saudi Arabia has been previously published by Alsager
et al. [1]. This comparison primarily utilises the results
from the second and third sections of the questionnaire for
Saudi Arabia, Canada, Singapore, and Australia.
4 Results
4.1 Processes
The key features of the SFDA review process compared
with that of Health Canada, the HSA, and the TGA are
summarised in Fig. 1.
4.1.1 Review Model
Three models used by regulators for the scientific review of
a product have been identified by McAuslane et al. [5]. The
type 1 model (the verification assessment model) avoids
duplicating the assessment of a new product that is identical
to one that has been approved elsewhere. This model
requires prior recognition of an authorisation by two or
more reference or competent benchmark authorities and
incorporates a verification process to validate the status of a
product and to ensure that the medicine to be marketed
locally conforms to the authorised product. The type 2
model (the abridged assessment model) also requires that
the product has been registered by at least one reference or
competent benchmark authority and conserves resources by
not re-assessing the full scientific supporting data. This
model focuses on aspects that must be evaluated specifically
for the local environment, and an abridged assessment is
carried out in relation to the use of the product under local
conditions, for example, focusing on aspects of quality such
as stability, benefit–risk assessment for the local medical
practice or culture, and patterns of disease. In the type 3A
and 3B model (the full assessment model), the authority has
suitable resources, including access to appropriate internal
and external experts, to carry out a complete review and
evaluation of the supporting scientific data. In type 3A
reviews, quality, safety (pre-clinical), and efficacy (clinical)
data are assessed in detail and there are requirements for
pre-registration in another jurisdiction before an authori-
sation can be finalised. In type 3B reviews, a full, inde-
pendent review of safety (pre-clinical) and efficacy
(clinical) data is carried out and information from regis-
trations in other jurisdictions (if any) is taken into consid-
eration, but is not a prerequisite to filing or authorisation.
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The SFDA conducts a type 3A (full assessment)
review, in which quality, safety (pre-clinical), and effi-
cacy (clinical) data are assessed in detail, and there are
requirements for pre-registration elsewhere before the
authorisation can be finalised. Canada and Australia
conduct a type 3B review, which does not require an
approval by a reference country. The type 2 or abridged
assessment is also conducted in Australia; however,
guidelines stipulate that the drug product has to be
approved by two or more reference agencies and the drug
must be identical to that in the reference countries.
Although Singapore uses all three routes of assessment—
verification (type 1), abridged (type 2), and full review
(type 3)—the majority of its evaluations are abridged
reviews.
4.1.2 Certificate of Pharmaceutical Product
The SFDA requires a legalised Certificate of Pharmaceu-
tical Product (CPP) at the time of application; however, if
the product has not been approved elsewhere and has been
designated as a priority product, the CPP can be submitted
at the time of authorisation rather than at the time of
submission. The World Health Organization (WHO) has
stated that legalisation of the CPP is no longer required,
and Canada, Singapore, and Australia do not require a CPP.
4.1.3 Data Requirements
The SFDA currently requires full pharmaceutical, chem-
istry, manufacturing, and controls (CMC), non-clinical, and
Fig. 1 Summary comparison of
key features of the
pharmaceutical regulatory
systems of Saudi Arabia,
Canada, Singapore, and
Australia. NAS new active
substance
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clinical data with submissions. The agency conducts a
detailed assessment of the pharmaceutical/CMC and clin-
ical data, whereas the non-clinical data are only reviewed if
a query has been raised. In addition, Saudi Arabia requires
information relating to pricing as part of their review
process.
Like the SFDA, Health Canada, the HSA, and the TGA
require full pharmaceutical, CMC, non-clinical, and clinical
data sets. The HSA carries out various assessments based on
the type of review, allowing the agency to utilise their
resources and expertise on applications for medicines that
have a high-risk factor for their population. Unlike the SFDA,
the agencies have separate groups that review pricing.
4.1.4 Target and Approval Timing
The SFDA review process consists of validation of the
dossier package, scientific assessment, company response
time, and final authorisation. The SFDA has stipulated
target times for validation, scientific assessment, authori-
sation and the overall approval time. The review of quality,
safety, and efficacy data is conducted in parallel, and the
primary scientific assessment is carried out internally, with
external experts used on an ad hoc basis for advice on
clinical matters or recommendations. The target timing for
scientific assessment in the SFDA is 354 calendar days and
for overall approval is 420 calendar days.
The target times for type 3B scientific assessment for
agencies in Health Canada, the HSA, and the TGA range
from 186 to 395 calendar days, with the authorisation
procedure for most agencies being within 1 month. The
overall target approval time for a type 3B review is
between 305 days in the TGA and 395 calendar days in the
HSA.
From 2011 to 2013, company-documented approval
times for NASs approved by the SFDA show variability,
ranging from 284 to 1377 calendar days, with a median of
521 days. Whilst it should be recognised that these data are
from a limited number of companies, agency-provided data
also show a large variance in approval times, ranging from
198 to 893 calendar days, with a median approval time of
340 calendar days, which is in line with SFDA target times.
Target and approval times for NASs from 2011 to 2013
according to company-supplied and agency-supplied data
for the SFDA, Health Canada, the HSA, and the TGA are
shown in Fig. 2. It can be seen that the SFDA median
approval time for NASs is comparable to those provided by
other agencies monitored in this study.
Fig. 2 Regulatory approval time from date of submission to date of
approval for NASs approved 2011–2013 in Saudi Arabia, Canada,
Singapore, and Australia. (n1, n2) number of drug applications,
number of companies providing data, boxes 25th and 75th percentiles,
whiskers 5th and 95th percentiles, diamonds company-provided data,
triangles agency target time, circles agency-provided data (from
agency and public domain). Singapore company data shows approval
time for all review types, but the majority of the applications were an
abridged review. NA not available, NAS new active substance.
Asterisks Singapore target time shown for type 3B review (full
review); double asterisks NAS approval time shown for local and
international companies
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4.1.5 Lag Time
Dossiers for NASs submitted to the SFDA lag behind the
first approval in the world by a median of 1 year, whereas
they were submitted to the TGA within a median of 74
days prior to the completion of the first approval anywhere
in the world and to Health Canada 15 days after the first
approval anywhere in the world. The HSA submissions
reflect a slightly longer lag time in comparison to the TGA
and Health Canada; however, this analysis combines type
1, 2, and 3 reviews. The majority of HSA applications are
reviewed using a type 2 review model, which requires prior
approval from at least one other reference stringent agency
(Fig. 3). These differences in timing may reflect the
importance of the market and company strategy as well as
the requirements of the country. It should be noted that the
Fig. 3 Median time to rollout of NASs in Saudi Arabia, Australia,
Canada, and Singapore, 2011–2013. N in bar median number of days,
(n1, n2) number of NASs, number of companies. NASs in this
analysis include those with first anywhere in the world submission,
first anywhere in the world approval; application submission and
application approval dates only. Australia and Canada data are
provided from the public domain and from the agency. Singapore
company data show approval time for all review types, but the
majority of the applications underwent an abridged review. EM
emerging markets, NAS new active substance, TGA Therapeutic
Goods Administration
Fig. 4 Regulatory quality
measures at regulatory agencies
in Saudi Arabia, Canada,
Singapore, and Australia. (n1/
n2) number of measures in use
at the agency/number of
possible measures. GCC Gulf
Cooperation Council, SOPs
standard operating procedures.
Asterisks as part of the GCC
process; double asterisks
agency has an internal quality
audit programme framework
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data set for Saudi Arabia is very small, with only 15 NASs
and seven companies, so may not be a true representation
of the complete data set of approved products.
4.2 Good Review Practice
4.2.1 Quality Measures
The quality measures included in the agencies’ decision-
making processes and evaluated in this comparative
study included the use of an internal quality policy, good
review practices, the availability of standard operating
procedures (SOPs) for assessors, the use of assessment
templates, the availability of a quality assurance depart-
ment, the use of a scientific committee, and the use of
shared and joint reviews with other agencies. The SFDA
have five out of these seven measures in place, namely,
SOPs for assessors, assessment templates, a quality
assurance department, a scientific committee, and shared
and joint reviews employed for the GCC process; how-
ever, these good review practices are implemented
informally. Like the SFDA, Health Canada and the HSA
employ five of the seven measures, whilst the TGA uses
six. Of the four agencies, only the SFDA indicated that
they have established a quality assurance department
(Fig. 4).
Fig. 5 Transparency and
communication measures at
regulatory agencies in Saudi
Arabia, Canada, Singapore and
Australia. (n1/n2) number of
measures in use at the agency/
number of possible measures
Fig. 6 Continuous
improvement initiatives at
regulatory agencies in Saudi
Arabia, Canada, Singapore, and
Australia. (n1/n2) number of
measures in use at the agency/
number of possible measures.
NA not available
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4.2.2 Transparency and Communication
Information communicated by regulators to stakeholders
could include feedback on submitted dossiers, technical
staff contact information, pre-submission scientific advice,
official guidelines, ability to track the progress of appli-
cations, summary of the grounds of approval, approval
times, advisory committee meeting dates, and the approval
of products. The SFDA has five of these nine parameters,
the HSA has six, Health Canada eight, and the TGA all
nine. Of the four agencies, the SFDA, Health Canada, and
the HSA do not supply advisory meeting dates, the SFDA
and the HSA do not publish the Summary Basis of
Approval or give feedback to the industry on the submitted
dossier. The SFDA is the only agency that does not share
information that is needed to contact their technical staff
during the review (Fig. 5).
4.2.3 Continuous Improvement Initiatives
The continuous improvement initiatives assessed in this
study included external and internal quality audits, tracking
systems, and review of assessors’ and stakeholders’ feed-
back. The SFDA has all of these continuous improvement
processes in place, while the TGA and HSA have four and
Health Canada has three (Fig. 6).
4.2.4 Training and Education
The type of training and continuing education that can
enhance the review process include international work-
shops, external and in-house courses, on-the-job training,
lectures by external speakers, induction training,
sponsorship of postgraduate degrees, and placements and
secondments. The SFDA is in line with Health Canada, the
HSA and the TGA, employing all eight measures with
respect to training and education (Fig. 7).
4.2.5 Contributors and Barriers to Good-Quality Decision
Making
The SFDA questionnaire responses indicated that adaption
of international regulatory framework guidelines, training
of staff, and developing an electronic tracking system and
database for registered products are the major contributors
to an effective and efficient regulatory authority. Whilst the
other agencies provided a diverse set of enablers as part of
their questionnaire responses, there was some consistency
among all four agencies regarding the need for a focus on
good-quality review measures and qualified staff.
Factors that act as a barrier to the SFDA quality review
are the lack of experienced staff and a high turnover, the
lack of on-the-job training with international regulatory
authorities and the GCC process, all of which have an
impact on the national review approval timelines. The
comparative agencies indicated that incomplete submis-
sions were a barrier to an effective and efficient regulatory
authority in their jurisdiction.
5 Discussion
The SFDA currently conducts a full review assessment of
applications (type 3A), which is an appropriate methodol-
ogy based on the competency of the staff. However,
reviewer resources are limited, causing delays, and
Fig. 7 Training and education
initiatives at regulatory agencies
in Saudi Arabia, Canada,
Singapore, and Australia. (n1/
n2) number of measures in use
at the agency/number of
possible measures
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alternate methods should be considered. Regulatory agen-
cies should consider the use of a risk-stratification
approach that enables them to both conserve and utilise
constrained resources more efficiently [1]. The HSA and
TGA both employ such a risk-stratification approach, and
Health Canada is piloting this strategy for abridged reviews
(type 2). The HSA, while carrying out both full and
abridged reviews, also conducts a verification assessment
on products that have been approved by two or more ref-
erence agencies.
WHO guidelines no longer require a CPP for regulatory
submission; however, the SFDA currently conducts a full
review of dossiers with the requirement of a CPP at the
time of submission, which can cause delays in submission
and consequent delays in patients’ access to medicines. The
SFDA currently maintains a submission pathway that
allows the CPP to be submitted at the time of authorisation
for certain products, and consideration should be given to
expanding these criteria for use of this pathway. In addi-
tion, the utilisation of other tools such as reference agency
websites to confirm marketing authorisation could expedite
patients’ access to medicines [7].
Some agencies in jurisdictions with emerging pharma-
ceutical markets such as Brazil, Mexico, Taiwan, and
Turkey only require the receipt of the CPP at the time of
market authorisation. The SFDA may wish to consider this
approach, which has resulted in a shorter lag time from first
approval anywhere in the world to submission in these
countries and an expedited rollout of new medicines and
their consequent availability to patients.
Defining target times within the review process allows
the agency and other stakeholders to plan for a more pre-
dictable outcome, and detailing each specific milestone in
the review process allows the identification of areas in
which improvements can be made. The SFDA has a robust
tracking system that monitors the key milestones of the
review process. In addition, median SFDA approval times
are within the stated targets; however, the appreciable
variability in approval times suggests the need for
improved consistency and process predictability in the
system. This may result from both a lack of experienced
staff and recent agency organisational changes. However,
one-third of SFDA review time (90 working days) is
allotted to company response times and this variability
could also result from irregularity in the time taken to
answer questions by the company.
HSA- and TGA-supplied data show approval times that
are shorter than the data for approval times supplied by
pharmaceutical companies, but this analysis is based on a
small data set from a limited number of companies. Health
Canada target and approval times are relatively similar and
this may be because Canada is governed by the User Fees
Act, which includes penalties of up to 50 % for non-
adherence to service standards, and the agency has taken
measures to ensure adherence to timelines to avoid a loss in
revenue and thus a resulting reduction in regulatory
resources.
In addition to the SFDA CPP requirements, pricing
negotiations at the regulatory agency add to the product
approval timing in Saudi Arabia. As part of these pricing
negotiations, the SFDA requires a pricing list from 12
countries where the product has been approved, which then
increases the lag time to submission in Saudi Arabia after
first approval anywhere in the world. All of the three
comparative agencies in this study maintain a separation of
pricing and regulatory functions.
According to the recently published WHO guidelines on
good review practices, the employment of good review
practices can expedite patients’ access to important medici-
nes by facilitating a timely, quality regulatory review and can
also maximise the use of scarce resources by enabling reg-
ulatory convergence [8]. Like Health Canada, the HSA, and
the TGA, the SFDA currently has all the fundamental quality
measures in place, to improve and ensure consistency and
process predictability; however, the SFDA should consider
establishing a formal good review practices system, which
would ensure the implementation of that system.
Processes for good decision making enable improved
communication to stakeholders [9]; however, neither the
SFDA nor the HSA publish a summary of the grounds on
which approval is granted; that is, a Summary Basis of
Approval or similar documentation. Should the SFDA
consider the provision of such documentation, this would
provide transparency to patients and healthcare providers
regarding internal decision making. In addition, providing
feedback on the dossier to industry is a form of commu-
nication that could enhance the quality of future submis-
sions, thus minimising errors and reducing deficiency
questions during the review [10]. The SFDA employs more
continuous improvement processes than Health Canada,
the HSA, or the TGA, reflecting the considerable efforts it
is making to evolve agency competency to become a
Centre of Excellence in the Gulf Region.
Training is a fundamental requirement for quality, pre-
dictability, and capacity building of regulatory processes
[11], and training measures have been implemented at the
SFDA to develop the expertise of the staff. The introduc-
tion of additional in-house training methods and the pro-
vision of education incentives could help retain staff and
promote consistent practices. One of the best methods for
training is ‘‘job shadowing’’ an assessor from another
agency, and it may be beneficial for the SFDA to develop
such a relationship with one or two reference agencies who
might be willing to place one of their reviewers at the
SFDA or allow the SFDA reviewers to be seconded to their
agency.
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It is recognised that a framework for a systematic
structured approach to benefit–risk assessment is critical to
a good-quality review [11]. The WHO good review prac-
tices guidelines specify that a review strategy should enable
the reviewer or review team to understand and describe the
benefit–risk profile of the medical product, given its indi-
cation and context of use. The Universal Methodology for
Benefit Risk Assessment (UMBRA) framework, which has
been evaluated and found to be fit for purpose by Health
Canada, the HSA, and the TGA [12] as well as by several
international regulatory agencies around the world [13],
may be a useful tool for SFDA decision making.
6 Conclusions
The country with the largest population and a dominating
economy in the Gulf Region is Saudi Arabia [14]. There-
fore, it was appropriate to compare the current SFDA
processes and practices with those of similar medium-size
regulatory agencies such as Health Canada, the HSA, and
the TGA. This has enabled the development of several
proposals to assist the agency in its efforts to become an
internationally recognised reference agency.
The SFDA should consider:
1. Exploring a risk-stratification approach based on the
Singapore model; that is, a verification review for
products that have been approved by two or more
reference agencies and an abridged review for medici-
nes approved by one or more agencies, with a full
review only employed for those products that have not
been reviewed elsewhere by a reference agency.
2. Replacing the requirement for a legalised CPP with
other data sources such as reference agencies’ websites
to confirm marketing authorisation. Alternatively, the
SFDA could require receipt of the CPP at the time of
market authorisation rather than at the time of
submission.
3. Investigating the separation of pricing negotiations
from the review process to remove a rate-limiting step
in the review process.
4. Publishing a Summary Basis of Approval or other
document that transparently communicates the ratio-
nale for agency decisions to stakeholders.
5. Introducing a feedback process to industry on the
quality of the dossier to improve future submissions
and decrease the number of deficiency questions,
thereby shortening the time required for the review.
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